{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:16:03Z","timestamp":1780449363706,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urolonc.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:16:13Z","timestamp":1751958973000},"page":"665.e1-665.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience"],"prefix":"10.1016","volume":"43","author":[{"given":"Esmail M.","family":"Al-Ezzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Abdeljalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya S.","family":"Gramolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Alqaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Odwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Almuthri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikaash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di Maria","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Fallah-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.06.004_bib0001","unstructured":"Canadian cancer society and national cancer institute of canada. Advisory Committee on Records and Statistics Canada Canadian Cancer Statistics 2023.Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canada, and the Public Health Agency of Canada. [2024]. Canadian Cancer Statistics [Prostate Cancer]. Toronto, ON: Canadian Cancer Society. Available at: cancer.ca\/Canadian-Cancer-Statistics-[2024]-EN (accessed [June 2025])."},{"key":"10.1016\/j.urolonc.2025.06.004_bib0002","series-title":"Encyclopedia of cell biology","first-page":"456","article-title":"DNA repair by homologous recombination","author":"Jenkins","year":"2016"},{"issue":"7381","key":"10.1016\/j.urolonc.2025.06.004_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.06.004_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2025.06.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.urolonc.2025.06.004_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.urolonc.2025.06.004_bib0008","first-page":"597","article-title":"A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer","volume":"55","author":"Lang","year":"2019","journal-title":"Int J Oncol"},{"issue":"7035","key":"10.1016\/j.urolonc.2025.06.004_bib0009","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.06.004_bib0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.10.021","article-title":"Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective","volume":"179","author":"Herzog","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.06.004_bib0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.06.004_bib0012","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.urolonc.2025.06.004_bib0013","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2025.06.004_bib0014","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.urolonc.2025.06.004_bib0015","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.004_bib0016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"12_Supplement","key":"10.1016\/j.urolonc.2025.06.004_bib0017","doi-asserted-by":"crossref","first-page":"CT031","DOI":"10.1158\/1538-7445.AM2022-CT031","volume":"82","author":"de Bono","year":"2022","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2025.06.004_bib0018","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-21-2096","article-title":"Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score","volume":"28","author":"Westphalen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2025.06.004_bib0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.06.004_bib0020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.06.004_bib0021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","article-title":"Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects","volume":"76","author":"Isaacsson Velho","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.06.004_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2020.05.001","article-title":"Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer","volume":"136","author":"van der Doelen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.06.004_bib0024","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urolonc.2010.07.002","article-title":"Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy","volume":"30","author":"Sonpavde","year":"2012","journal-title":"Urol Oncol: Sem Origin Investigat"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2025.06.004_bib0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1200\/JCO.2021.39.6_suppl.98","article-title":"Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"39","author":"Choudhury","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2025.06.004_bib0026","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"A Phase ib study of Atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.urolonc.2025.06.004_bib0027","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/pros.24375","article-title":"The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases","volume":"82","author":"Liu","year":"2022","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.urolonc.2025.06.004_bib0028","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.004_bib0029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair\u2013deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.06.004_bib0030","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.06.004_bib0031","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.06.004_bib0032","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.06.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088239","article-title":"DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy","volume":"9","author":"Graf","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.urolonc.2025.06.004_bib0034","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pros.24450","article-title":"Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: a single-center experience","volume":"83","author":"Satapathy","year":"2023","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.004_bib0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","article-title":"Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer","volume":"25","author":"Priv\u00e9","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.004_bib0036","article-title":"DNA damage repair defects and targeted radionuclide therapies for prostate cancer: does mutation really matter?","volume":"13","author":"Filippi","year":"2022","journal-title":"Syst Rev. Life (Basel)"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:33:10Z","timestamp":1762363990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1078143925002200"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}